Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

中生北控生物科技股份有限公司
BIOSINO BIO-TECHNOLOGY AND SCIENCE INCORPORATION

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 8247)

VOLUNTARY ANNOUNCEMENT

CHANGE OF SUBSTANTIAL SHAREHOLDER

This announcement is made by Biosino Bio-Technology and Science Incorporation (the "**Company**") on a voluntary basis.

The Company has recently received notification from Beijing Pusai Asset Management Co., Ltd.*(北京普賽資產管理有限責任公司)("**Beijing Pusai**") that Beijing Pusai entered into a Property Rights Transaction Contract on 18 December 2025 with Shandong Biobase Zhongsheng Technology Co., Ltd.*(山東博科中生科技有限公司)("**Biobase Zhongsheng**") pursuant to which it transferred its entire holding of 31,308,576 domestic shares in the Company (representing approximately 21.64% of the total issued share capital of the Company) to Biobase Zhongsheng in accordance with the law (the "**Transfer**"). The Transfer has completed the relevant procedures at the China Beijing Equity Exchange.

On 31 December 2025, both parties completed the procedures for share transfer registration and change of ownership at the relevant share registration authority. With effect from this date, Biobase Zhongsheng has formally become a shareholder of the Company holding approximately 21.64% of its shares.

Biobase Zhongsheng is a technology enterprise established in Shandong Province, the People's Republic of China, primarily engaged in medical device equipment, biomedical technology, medical informatisation and overall laboratory solutions. It is a comprehensive enterprise integrating research and development, production, sales and services. According to publicly available information, Biobase Zhongsheng is indirectly wholly owned by Gan Yiwu and Chu Danxia.

Immediately following completion of the Transfer, (a) Beijing Pusai no longer holds any interest in the shares of the Company and has ceased to be a substantial shareholder of the Company (as defined in the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited (the "**GEM Listing Rules**")); and (b) Biobase Zhongsheng holds 31,308,576 domestic shares in the Company (representing approximately 21.64% of the total issued share capital of the Company) and has become a substantial shareholder of the Company.

The table below sets out the shareholding structure of the Company (i) immediately before completion of the Transfer and (ii) immediately after completion of the Transfer and as at the date of this announcement:

	Prior to Completion of the Transfer Number of Shares	Approximate Percentage (%)	Upon Completion of the Transfer and as at the date of this Announcement Number of Shares	Approximate Equity Percentage (%)
Beijing Pusai	31,308,576 domestic shares	21.64	–	–
Biobase Zhongsheng	–	–	31,308,576 domestic shares	21.64
Hong Kong Zhixin Investment Limited *(Note 1)*	27,256,143 H shares	18.84	27,256,143 H shares	18.84
Mr. Li Yangyixiong and Yunnan Shengneng Investment Partnership (Limited Partnership) *(Note 2)*	11,989,577 domestic shares and 6,780,000 H shares	12.97	11,989,577 domestic shares and 6,780,000 H shares	12.97
Jingning Guoke Kangyi Enterprise Management Center LLP *(Note 3)*	11,330,334 domestic shares	7.83	11,330,334 domestic shares	7.83
Sichuan Zhongsheng Medical Instrument Co., Ltd. *(Note 4)*	10,000,000 domestic shares	6.91	10,000,000 domestic shares	6.91
Mr. Wu Lebin	3,500,878 domestic shares	2.42	3,500,878 domestic shares	2.42
Public Shareholders	12,291,668 domestic shares and 30,250,000 H shares	29.40	12,291,668 domestic shares and 30,250,000 H shares	29.40
Total	80,421,033 domestic shares and 64,286,143 H shares	100.00	80,421,033 domestic shares and 64,286,143 H shares	100.00

Notes:

1. Hong Kong Zhixin Investment Limited*（香港智昕投資有限公司）("**Hong Kong Zhixin**") was wholly owned by Hainan Zhixin Investment Partnership (Limited Partnership)*（海南智昕投資合夥企業（有限合夥））("**Hainan Zhixin**"). Hainan Zhixin was owned as to approximately 36.01% and 36.01% of its interests by Mr. Chen Peng (an Executive Director and the President of the Company) and Mr. Li Dongfeng, respectively. Mr. Chen Peng is currently the Executive Affairs Partner and General Partner of Hainan Zhixin. Accordingly, pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the "**Securities and Futures Ordinance**"), each of Mr. Chen Peng and Mr. Li Dongfeng was deemed to have interests in the H Shares held by Hong Kong Zhixin.

2. Mr. Li Yangyixiong currently owns approximately 43.12% of the interests in Yunnan Shengneng Investment Partnership (Limited Partnership)*（雲南勝能投資合夥企業（有限合夥））("**Yunnan Shengneng**"). Accordingly, Mr. Li Yangyixiong was deemed to be interested in the H shares and domestic shares held by Yunnan Shengneng under the Securities and Futures Ordinance.

3. Mr. Chen Peng, an Executive Director and the President of the Company, was indirectly interested in 11,330,334 domestic shares through Jingning Guoke Kangyi Enterprise Management Centre LLP* 景寧國科康儀企業管理中心（有限合夥）("**Jingning Guoke**"). Jingning Guoke was owned as to 99.5% interests by Mr. Chen Peng (an Executive Director and the President of the Company). Accordingly, Mr. Chen Peng was deemed to be interested in the domestic shares held by Jingning Guoke under the Securities and Futures Ordinance.

4. Mr. Chen Zhengyong, an Executive Director and the Chairman of the Board of the Company, was indirectly interested in 10,000,000 domestic shares through Sichuan Zhongsheng Medical Instrument Co., Ltd.* 四川中生醫療器械有限責任公司 ("**Sichuan Zhongsheng**"). Sichuan Zhongsheng was owned as to approximately 77.94% equity interests by Mr. Chen Zhengyong (an Executive Director and the Chairman of the Board). Accordingly, Mr. Chen Zhengyong was deemed to be interested in the domestic shares held by Sichuan Zhongsheng under the Securities and Futures Ordinance.

* *For identification purposes only*

For and on behalf of the Board
Biosino Bio-Technology and Science Incorporation
Chen Zhengyong
Chairman

Beijing, China, 31 December 2025

As at the date of this announcement, the members of the Board comprise:

Chairman and Executive Director
Mr. Chen Zhengyong

Vice Chairman and Executive Director
Mr. Li Zhonghua

President and Executive Director
Mr. Chen Peng

Vice Chairman and Non-executive Director
Mr. Yang Peng

Non-executive Directors
Dr. Gao Guangxia and Dr. Shen Sheng

Independent non-executive Directors
Prof. Shen Zuojun, Prof. Shen Jiangang, Dr. He Xin and Mr. Fan Xiaoliang

This announcement is made in compliance with the requirements of the GEM Listing Rules to disclose information concerning the Company. The Directors jointly and severally accept full responsibility for the accuracy of the information contained in this announcement and confirm, having made all reasonable enquiries, that to the best of their knowledge and belief: (1) the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive; and (2) there are no other matters the omission of which would make any statement in this announcement misleading.

This announcement will remain on the "Latest Listed Company Announcements" page on the website of the Stock Exchange at www.hkexnews.hk for at least 7 days from the date of its publication and on the Company's website at www.zhongsheng.com.cn.